Clinical Trials Logo

Chronic Kidney Disease 5D clinical trials

View clinical trials related to Chronic Kidney Disease 5D.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06126016 Recruiting - Clinical trials for Secondary Hyperparathyroidism

A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.

Start date: October 19, 2023
Phase:
Study type: Observational

The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis

NCT ID: NCT05805813 Recruiting - Clinical trials for Chronic Kidney Disease 5D

Cross-control Study on the Effect of Peritoneal Rest on Peritoneal Transport Function in Peritoneal Dialysis Patients

CSEPR
Start date: April 20, 2023
Phase: N/A
Study type: Interventional

The investigators will carry out a prospective cross-over, pre-and post-controlled clinical study : 36 patients with continuous ambulatory peritoneal dialysis with high/high average transport will be recruited and treated with continuous ambulatory peritoneal dialysis and intermittent peritoneal dialysis at night (using automatic peritoneal dialysis machine) for 1 month respectively. The changes of peritoneal transport function and ultrafiltration volume before and after the two dialysis methods will be compared.

NCT ID: NCT05549154 Recruiting - Clinical trials for Vitamin D Deficiency

A Study on Prevention Strategies for CKD-SHPT and Related Complications Based on General Vitamin D Supplementation

Start date: December 5, 2022
Phase: N/A
Study type: Interventional

1. Study content: This is a multicentre, double-blind, randomised controlled study to determine the optimal dose and duration of treatment for the correction of vitamin D insufficiency or deficiency in patients with CKD5d; to investigate whether vitamin D supplementation delays the increase in PTH levels in this group of patients; and to investigate the effects on changes in CKD-MBD-related markers, cardiovascular complications, cognitive function in this group of patients. 2. Study procedure: Based on the inclusion and exclusion of the patients, the study was conducted in accordance with the following criteria 2. Study procedure: Eligible subjects were screened according to inclusion and exclusion criteria and randomly divided into three groups: high-dose vitamin D group, low-dose vitamin D group and control group. Baseline data were collected before the intervention and each group was given different doses of regular vitamin D2 softgels or placebo and followed up. 25(OH)D, PTH, blood Ca, and blood P levels were measured every month; bone metabolism markers, FGF23, and blood counts, liver function, kidney function, lipids, and blood glucose were measured every 3 months; the prevalence of vascular calcification, the incidence of cardiovascular events, and changes in cognitive function scale scores were assessed 6 months after the intervention.

NCT ID: NCT05339009 Recruiting - Clinical trials for Chronic Kidney Disease 5D

Bio-ADM as a Biomarker of Refilling in Chronic Hemodialysis Patient

REFILBIOADM
Start date: April 1, 2022
Phase:
Study type: Observational

Aim of this study is to evaluate in a population of chronic kidney disease patients on dialysis (Stage 5D) the predictive value of bio-adrenomedullin (bio-ADM) level on vascular refilling rate.

NCT ID: NCT05071131 Recruiting - Clinical trials for Chronic Kidney Disease 5D

Effect of Inulin on Gut Microbiota and Gut Barrier in Chronic Kidney Disease

RESTORE
Start date: February 1, 2022
Phase: N/A
Study type: Interventional

An adequate fiber intake is crucial for a well-balanced diet and reduces the risk of chronic diseases. However, nutritional recommendations for chronic kidney disease patients lead to an insufficient fiber intake with possible maladaptive effects on the gut microbiome. Therefore, we want to study the effects of a 35-day inulin supplementation on the gut microbiome, gut barrier function, bacterial metabolites and immune cell states in chronic kidney disease patients.